(AOF) – Mauna Kea Technologie, inventor of Cellvizio, the multidisciplinary platform for confocal laser endomicroscopy by probe and by needle, today announces its sales for the fourth quarter of 2022 at 2.65 million euros, up 2% compared to compared to the fourth quarter of 2021. The company underlines the maintenance of its level of activity in the United States at 4.2 million euros in 2022 despite sales teams reduced by 60% following the “strategic repositioning” of the group.
Mauna Kea announces that its total sales for the year 2022 are down slightly by 3% and amount to 7.479 million euros, a level in line with expectations. In the United States, sales were stable, at 4.202 million euros, nevertheless impacted by a slowdown in activity in the second half following difficulties in the supply of contrast agent (fluorescein) which significantly affected the number of Cellvizio procedures.
The recovery of activity in EMEA (Europe, Middle East and Africa) & Rest of the World (ROW) in the second half enabled the company to record a 47% increase in sales in this region during the year. year 2022, thus neutralizing the decline in sales in the Asia-Pacific region, due to the signing of the partnership with Tasly Pharmaceutical.
“We approach 2023 with strong sales productivity in the United States, an interesting commercial dynamic in EMEA and ROW, a new strategic partnership with Tasly, a reduced rate of cash consumption and above all, a more rigorous and more efficient overall organization. “, said Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.